alpha-(n6-adenyl)styrene oxide profile

alpha-(N6-adenyl)styrene oxide: structure given in first source; RN given refers to compound with no isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	124293
CHEMBL ID	1367143
SCHEMBL ID	2623141
SCHEMBL ID	17933810
MeSH ID	M0254314

Synonym
REGID7969507
IFLAB1_002363
OPREA1_551360
MLS000101215 ,
smr000017460
n-(1-phenylethyl)-7h-purin-6-amine
AKOS001063562
HMS1418L09
AB00433751-04
NCGC00081764-02
NCGC00168501-01
STK980622
n-(1-phenylethyl)-9h-purin-6-amine
AKOS005853545
HMS2249C11
n-(1-phenylethyl)-1h-purin-6-amine
(r)-alpha-(n(6)-adenyl)styrene oxide
1h-purin-6-amine, n-(1-phenylethyl)-
alpha-(n6-adenyl)styrene oxide
55553-54-3
alpha-n6-ad-so
6-phenylethylaminopurine
F0578-0063
AKOS016332226
SCHEMBL2623141
CHEMBL1367143
1-phenylethyl(7h-purin-6-yl)amine
cid_124293
bdbm38842
SCHEMBL17933810
Z56935828
SR-01000007303-1
sr-01000007303
6-(a-methylbenzylamino)purine
adenine,6n-(1-phenylethyl)
DTXSID00874405
cl-16625

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	19.9526	0.0447	17.8581	100.0000	AID485294
Chain A, HADH2 protein	Homo sapiens (human)	Potency	31.6228	0.0251	20.2376	39.8107	AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	31.6228	0.0251	20.2376	39.8107	AID893
Chain A, Cruzipain	Trypanosoma cruzi	Potency	7.9433	0.0020	14.6779	39.8107	AID1476
TDP1 protein	Homo sapiens (human)	Potency	14.6777	0.0008	11.3822	44.6684	AID686978; AID686979
apical membrane antigen 1, AMA1	Plasmodium falciparum 3D7	Potency	31.6228	0.7079	12.1943	39.8107	AID720542
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	8.9125	0.2818	9.7212	35.4813	AID2326
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	100.0000	3.5481	19.5427	44.6684	AID743266
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	14.1254	0.0079	8.2332	1,122.0200	AID2551
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	11.2202	0.1259	12.2344	35.4813	AID1458
lamin isoform A-delta10	Homo sapiens (human)	Potency	35.4813	0.8913	12.0676	28.1838	AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID652178	Confirmed Agonists of Novel Allosteric Modulators of the M1 Muscarinic Receptor	2013	Molecules (Basel, Switzerland), Jan-08, Volume: 18, Issue:1	Benchmarking ligand-based virtual High-Throughput Screening with the PubChem database.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	1 (12.50)	29.6817
2010's	5 (62.50)	24.3611
2020's	1 (12.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	1.98	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	2.08	1	dialkylarylamine; tertiary amino compound
spiperone Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.	2.08	1	aromatic ketone; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	alpha-adrenergic antagonist; antipsychotic agent; dopaminergic antagonist; psychotropic drug; serotonergic antagonist
pilocarpine hydrochloride pilocarpine hydrochloride : The hydrochloride salt of (+)-pilocarpine, a medication used to treat increased pressure inside the eye and dry mouth.	2.08	1	hydrochloride
rhein [no description available]	2.08	1	dihydroxyanthraquinone
bethanechol chloride bethanechol chloride : The chloride salt of bethanechol. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.	2.08	1	carbamate ester; chloride salt; quaternary ammonium salt	muscarinic agonist
n-(cyclohexylthio)phthalimide N-(cyclohexylthio)phthalimide: water pollutant	2.08	1
oxcarbazepine Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.. oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.	2.08	1	cyclic ketone; dibenzoazepine	anticonvulsant; drug allergen
ergocornine ergocornine: a component of ergotoxine; minor descriptor (75-86); on-line & INDEX MEDICUS search ERGOLINES (75-86); RN given refers to ((5'alpha)-isomer). ergocornine : Ergotaman bearing a hydroxy group at the 12' position, isopropyl groups at the 2' and 5'alpha positions, and oxo groups at positions 3', 6', and 18. It is a natural ergot alkaloid.	2.08	1	ergot alkaloid
butyrylcholine chloride [no description available]	2.08	1
monopentyl phthalate monopentyl phthalate : A phthalic acid monoester obtained by formal condensation of one of the carboxy groups of phthalic acid with the hydroxy group of pentanol.	2.08	1	phthalic acid monoester	anti-estrogen; rat metabolite; xenobiotic metabolite
7-amino-4-trifluoromethylcoumarin coumarin 151: structure in first source	2.08	1	7-aminocoumarins	fluorochrome
2-[[2-[[4-(2-furanylmethyl)-5-(phenylmethyl)-1,2,4-triazol-3-yl]thio]-1-oxoethyl]amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide [no description available]	2.08	1	aromatic amide; thiophenes
1-(1,3-benzodioxol-5-ylmethyl)-3-hydroxy-3-[2-(4-methylphenyl)-2-oxoethyl]-2-indolone [no description available]	2.08	1	aromatic ketone
6-ethyl-N-[2-(4-methoxyphenyl)ethyl]-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine [no description available]	2.08	1	triazolopyrimidines
7-[2-hydroxy-3-(2-methylphenoxy)propyl]-3-methyl-8-(propan-2-ylthio)purine-2,6-dione [no description available]	2.08	1	oxopurine
2-[[5-(1-benzotriazolylmethyl)-1,3,4-oxadiazol-2-yl]thio]-N-[(4-fluorophenyl)methyl]-N-phenylacetamide [no description available]	2.08	1	benzotriazoles
3-[(1-cyclopentyl-5-tetrazolyl)-[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-7-methyl-1H-quinolin-2-one [no description available]	2.08	1	piperazines
3-[[2-[[5-[(4-cyanophenoxy)methyl]-4-phenyl-1,2,4-triazol-3-yl]thio]-1-oxoethyl]amino]benzoic acid methyl ester [no description available]	2.08	1	amidobenzoic acid
[5-(2-furanyl)-7-(trifluoromethyl)-2-pyrazolo[1,5-a]pyrimidinyl]-[4-(2-pyridinyl)-1-piperazinyl]methanone [no description available]	2.08	1	piperazines; pyridines
N-[2-[(3-cyano-6-ethoxy-2-quinolinyl)amino]ethyl]propanamide [no description available]	2.08	1	aminoquinoline
4-[3-(1,3-dioxo-2-isoindolyl)propylamino]-2-methylisoindole-1,3-dione [no description available]	2.08	1	phthalimides
9-[3-(4-acetyl-3,5-dimethyl-1-pyrazolyl)-2-hydroxypropyl]-6-methyl-3,4-dihydro-2H-carbazol-1-one [no description available]	2.08	1	carbazoles
1-phenyl-4-[[1-(phenylmethyl)-5-tetrazolyl]-(3-pyridinyl)methyl]piperazine [no description available]	2.08	1	piperazines
1-[(5,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-1-(2-furanylmethyl)-3-phenylurea [no description available]	2.08	1	quinolines
N-(2-furanylmethyl)-2-[(4-methoxyphenyl)sulfonylamino]benzamide [no description available]	2.08	1	sulfonamide
N-methyl-N-[5-(5-methyl-2-pyrazinyl)-1,3,4-thiadiazol-2-yl]-2-oxolanecarboxamide [no description available]	2.08	1	pyrazines
2-[[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]thio]-3-ethyl-4-quinazolinone [no description available]	2.08	1	quinazolines
2-[[5-(4-methylphenyl)-3-thiazolo[2,3-c][1,2,4]triazolyl]thio]-N-(6-methyl-2-pyridinyl)acetamide [no description available]	2.08	1	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
4-amino-N5-[2-(2-methoxyethylamino)-1-(5-methyl-2-furanyl)-2-oxoethyl]-N5-(thiophen-2-ylmethyl)isothiazole-3,5-dicarboxamide [no description available]	2.08	1	organonitrogen compound; organooxygen compound
pilocarpine nitrate [no description available]	2.08	1
7-diethylaminocoumarin-3-carboxylic acid [no description available]	2.08	1
5-(4-methoxyphenyl)-7-(4-methylphenyl)-1,7-dihydrotetrazolo[1,5-a]pyrimidine [no description available]	2.08	1	methoxybenzenes
cyclopropanecarboxylic acid [5-(6-amino-5-cyano-3-methyl-2,4-dihydropyrano[2,3-c]pyrazol-4-yl)-2-ethoxyphenyl] ester [no description available]	2.08	1	pyranopyrazole
2-cyano-2-[3-(4-morpholinyl)-2-quinoxalinyl]acetic acid cyclohexyl ester [no description available]	2.08	1	quinoxaline derivative
2-(3-methylphenyl)sulfonyl-2-[3-(1-pyrrolidinyl)-2-quinoxalinyl]acetonitrile [no description available]	2.08	1	quinoxaline derivative
5-(3-methoxyphenyl)-N-(2-oxolanylmethyl)-7-(trifluoromethyl)-3-pyrazolo[1,5-a]pyrimidinecarboxamide [no description available]	2.08	1	pyrimidines
2-(4-bromophenyl)-4-methyl-1H-pyrazol-5-one [no description available]	2.08	1	pyrazoles; ring assembly
2-[(4-fluoro-3-methylphenyl)sulfonylamino]acetic acid [no description available]	2.08	1	sulfonamide
4-(1H-benzimidazol-2-yl)quinoline [no description available]	2.08	1	quinolines
2-[[2-(5,6-dimethyl-1-benzimidazolyl)-1-oxoethyl]amino]benzoic acid methyl ester [no description available]	2.08	1	amidobenzoic acid
1-(4-ethylphenyl)-N-(3-pyridinylmethyl)methanamine [no description available]	2.08	1	aromatic amine
1-(4-ethoxyphenyl)-3-(6-quinoxalinyl)urea [no description available]	2.08	1	quinoxaline derivative
3-methyl-5-propyl-7-furo[3,2-g][1]benzopyranone [no description available]	2.08	1	psoralens
4-(1,3-benzothiazol-2-yl)-N-phenyl-1-piperazinecarboxamide [no description available]	2.08	1	N-arylpiperazine
2-[4-(pyridin-4-ylmethylsulfamoyl)phenoxy]acetic acid methyl ester [no description available]	2.08	1	monocarboxylic acid
5-bromo-N-(pyridin-4-ylmethyl)-2-thiophenesulfonamide [no description available]	2.08	1	thiophenes
LSM-16463 [no description available]	2.08	1	pyrazoles; ring assembly
4-[2-(9-methyl-6-indolo[3,2-b]quinoxalinyl)ethyl]morpholine [no description available]	2.08	1	quinoxaline derivative
4-[[[3-(4-morpholinylsulfonyl)phenyl]-oxomethyl]amino]benzoic acid ethyl ester [no description available]	2.08	1	benzamides
5-(2,3-dihydroindol-1-ylsulfonyl)-1,3-diethyl-2-benzimidazolone [no description available]	2.08	1	benzimidazoles
N-[2-(4-acetyl-1-piperazinyl)phenyl]-2-(5-methyl-2-propan-2-ylphenoxy)acetamide [no description available]	2.08	1	piperazines
N-(2-furanylmethyl)-2-imino-5-oxo-1-(2-phenylethyl)-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarboxamide [no description available]	2.08	1	pyridopyrimidine
N-[2-[4-[(4-chlorophenyl)-oxomethyl]-1-piperazinyl]phenyl]-1,3-benzodioxole-5-carboxamide [no description available]	2.08	1	aromatic amide
[2-(4-methoxyphenyl)-6-methyl-4-quinolinyl]-(4-morpholinyl)methanone [no description available]	2.08	1	quinolines
2-(2-furanyl)-5-methyl-6-(phenylmethyl)-1H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one [no description available]	2.08	1	triazolopyrimidines
1-[4-[(2-amino-5-thiazolyl)methyl]phenyl]ethanone [no description available]	2.08	1	aromatic ketone
N-[2-[4-[(4-chlorophenyl)-oxomethyl]-1-piperazinyl]phenyl]-2-benzofurancarboxamide [no description available]	2.08	1	aromatic amide; furans
2-(3,5-dimethylphenoxy)-N-[3-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]phenyl]acetamide [no description available]	2.08	1	anilide
5-(2-furanyl)-N-[1-[(2-methylphenyl)methyl]-3-pyrazolyl]-7-(trifluoromethyl)-3-pyrazolo[1,5-a]pyrimidinecarboxamide [no description available]	2.08	1	pyrazolopyrimidine
1,4-dioxa-8-azaspiro[4.5]decan-8-yl-(5,7-diphenyl-2-pyrazolo[1,5-a]pyrimidinyl)methanone [no description available]	2.08	1	pyrimidines
4-amino-2-[[4-(1-azepanylsulfonyl)phenyl]-oxomethyl]isoindole-1,3-dione [no description available]	2.08	1	phthalimides
N-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-2-[(6-methyl-1H-benzimidazol-2-yl)thio]acetamide [no description available]	2.08	1	pyrazoles; ring assembly
2-(1-benzimidazolyl)acetic acid [2-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] ester [no description available]	2.08	1	alpha-amino acid ester
2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-phenylacetamide [no description available]	2.08	1	amino acid amide
6-amino-5-cyano-4-(2,4-dimethoxyphenyl)-2-(2-ethoxy-2-oxoethyl)-4H-pyran-3-carboxylic acid ethyl ester [no description available]	2.08	1	dimethoxybenzene
2-chloro-5-[[2,3-dihydro-1,4-benzodioxin-3-yl(oxo)methyl]amino]benzoic acid methyl ester [no description available]	2.08	1	amidobenzoic acid
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methoxy-4-propan-2-yloxybenzamide [no description available]	2.08	1	benzodioxine
3-(3,4-dihydro-2H-quinolin-1-ylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine [no description available]	2.08	1	quinolines
benzoic acid [5-(6-benzamido-9-purinyl)-3-fluoro-4-hydroxy-2-oxolanyl]methyl ester [no description available]	2.08	1	3'-deoxyribonucleoside; purines
2-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonylamino)benzoic acid thiophen-2-ylmethyl ester [no description available]	2.08	1	benzoate ester
2-benzoyl-N-(6-methoxy-3-pyridinyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide [no description available]	2.08	1	isoquinolines
3,5-dimethyl-1-phenyl-4-pyrazolecarboxylic acid [2-[4-amino-1-methyl-3-(2-methylpropyl)-2,6-dioxo-5-pyrimidinyl]-2-oxoethyl] ester [no description available]	2.08	1	pyrazoles; ring assembly
9-chloro-6-methylindolo[3,2-b]quinoxaline [no description available]	2.08	1	quinoxaline derivative
3-chloro-N-[2-[4-(4-fluorophenyl)-1-piperazinyl]-2-(3-pyridinyl)ethyl]benzamide [no description available]	2.08	1	piperazines
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]propanamide [no description available]	2.08	1	oxadiazole; ring assembly
2-cyclopentyl-4-[1,4-dioxa-8-azaspiro[4.5]decan-8-yl(oxo)methyl]-9-methyl-1-pyrido[3,4-b]indolone [no description available]	2.08	1	beta-carbolines
N-(3-chlorophenyl)-5-(1,4-dioxa-8-azaspiro[4.5]decan-8-ylsulfonyl)-3-methyl-2-benzofurancarboxamide [no description available]	2.08	1	aromatic amide; furans
[4-[6-(4-morpholinyl)-3-pyridazinyl]-1-piperazinyl]-(2-pyridin-4-yl-4-quinolinyl)methanone [no description available]	2.08	1	quinolines
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(3-methyl-4-oxo-1-phthalazinyl)acetamide [no description available]	2.08	1	phthalazines
5-bromo-N-[2-(6,7-dimethyl-2-oxo-1H-quinolin-3-yl)ethyl]-2-furancarboxamide [no description available]	2.08	1	quinolines
3-(2-chlorophenyl)-5-methyl-N-[3-(3-methyl-2-imidazo[1,2-a]pyrimidinyl)phenyl]-4-isoxazolecarboxamide [no description available]	2.08	1	aromatic amide
7-(5-chloro-2-methoxyanilino)-6-[(4-methoxyphenyl)methyl]-7H-pyrrolo[3,4-b]pyridin-5-one [no description available]	2.08	1	pyrrolopyridine
2-furanyl-[4-(4-tetrazolo[1,5-a]quinoxalinyl)-1-piperazinyl]methanone [no description available]	2.08	1	N-arylpiperazine
[4-(2-pyrimidinyl)-1-piperazinyl]-[1-[4-(2-pyrimidinyl)-1-piperazinyl]-4-isoquinolinyl]methanone [no description available]	2.08	1	piperazines; pyridines
N-[[4-(dimethylamino)phenyl]methyl]-3-ethyl-N-(2-furanylmethyl)-5-methyl-4-oxo-6-thieno[2,3-d]pyrimidinecarboxamide [no description available]	2.08	1	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
N-(2,3-dimethylphenyl)-3-methyl-5-(4-morpholinylsulfonyl)-2-benzofurancarboxamide [no description available]	2.08	1	aromatic amide; furans
N-[(2-methyl-4-thiazolyl)methyl]-4-phenoxybenzenesulfonamide [no description available]	2.08	1	aromatic ether
4-[[3-[(2-furanylmethylamino)-oxomethyl]-7-methoxy-1-benzopyran-2-ylidene]amino]benzoic acid [no description available]	2.08	1	1-benzopyran
N-(2-furanylmethyl)-1-[2-(2-hydroxyethoxy)ethyl]-2-imino-10-methyl-5-oxo-3-dipyrido[3,4-c-1',2'-f]pyrimidinecarboxamide [no description available]	2.08	1	pyridopyrimidine
1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-3-piperidinecarboxamide [no description available]	2.08	1	benzodioxine
4-[4-oxo-2-[[2-oxo-2-[(phenylmethyl)amino]ethyl]thio]-3-quinazolinyl]-1-piperidinecarboxylic acid ethyl ester [no description available]	2.08	1	quinazolines
8-(2-propoxyphenyl)-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]quinolin-6-one [no description available]	2.08	1	quinolines
N-[4-[5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]-4-pyridinecarboxamide [no description available]	2.08	1	aromatic amide
3-(5,7-diphenyl-1,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-1-propanol [no description available]	2.08	1	triazolopyrimidines
methysergide maleate [no description available]	2.08	1	ergoline alkaloid
morin morin: a light yellowish pigment found in the wood of old fustic (Chlorophora tinctoria). morin : A pentahydroxyflavone that is 7-hydroxyflavonol bearing three additional hydroxy substituents at positions 2' 4' and 5.	2.08	1	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine [no description available]	2.08	1	triazolopyrimidines
4-[[[2-(4-methoxyphenyl)-3-oxo-1H-isoindol-4-yl]-oxomethyl]amino]-1-piperidinecarboxylic acid ethyl ester [no description available]	2.08	1	isoindoles
1,5-dimethyl-4-oxo-N-[2-(3-thiophenyl)ethyl]-2-pyrrolo[3,2-c]quinolinecarboxamide [no description available]	2.08	1	pyrroloquinoline
4-[[[1-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methyl]-3-piperidinyl]-oxomethyl]amino]-1-piperidinecarboxylic acid ethyl ester [no description available]	2.08	1	1,3-oxazoles
1,5-dimethyl-4-oxo-N-[3-(4-propyl-1-piperazinyl)propyl]-2-pyrrolo[3,2-c]quinolinecarboxamide [no description available]	2.08	1	pyrroloquinoline
4-(4-tetrazolo[1,5-a]quinoxalinyl)morpholine [no description available]	2.08	1	quinoxaline derivative
1-cyclopentyl-1-[(4-oxo-1H-quinazolin-2-yl)methyl]-3-(phenylmethyl)urea [no description available]	2.08	1	quinazolines
7-hydroxyquinoline 7-hydroxyquinoline: structure in first source. quinolin-7-ol : A monohydroxyquinoline carrying a hydroxy substituent at position 7.	2.08	1	monohydroxyquinoline

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1

alpha-(n6-adenyl)styrene oxide

Description

Cross-References

Synonyms (37)

Protein Targets (11)

Potency Measurements

Bioassays (15)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.63

Study Types

alpha-(n6-adenyl)styrene oxide

Description

Cross-References

Synonyms (37)

Protein Targets (11)

Potency Measurements

Bioassays (15)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.63

Study Types

Related Drugs (105)

Related Conditions (4)